Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.39 |
| ▸ | FEN1 | P39748 | 2/20 | 0.39 |
| ▸ | CTSA | P10619 | 2/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | MBNL1 | Q9NR56 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | APEX1 | P27695 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | MPL | P40238 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21091358 | 0.81 | HPGD (0.43) | KDM4EALDH1A1NPC1ALOX5APFEN1 | |
| SCHEMBL2404342 | 0.78 | ALDH1A1 (0.53) | MAPK14KDM4EALDH1A1NPC1ALOX5AP | |
| SCHEMBL5536331 | 0.78 | KDM4E (0.41) | MAPK14KDM4EALDH1A1NPC1ALOX5AP | |
| SCHEMBL29993395 | 0.78 | ALDH1A1 (0.53) | MAPK14KDM4EALDH1A1NPC1ALOX5AP | |
| SCHEMBL12947909 | 0.78 | ALDH1A1 (0.43) | KDM4EALDH1A1NPC1ALOX5APFEN1 | |
| SCHEMBL2440919 | 0.78 | LIMK1 (0.48) | MAPK14 | |
| SCHEMBL2409309 | 0.77 | HSD11B1 (0.47) | ALDH1A1ALOX5APFEN1TDP1 | |
| SCHEMBL25105387 | 0.76 | ESR1 (0.40) | ALDH1A1CTSANPSR1 | |
| SCHEMBL30229143 | 0.76 | NPSR1 (0.44) | CASRALDH1A1NPSR1 | |
| SCHEMBL2444868 | 0.76 | CTSA (0.41) | CASRMAPK14CTSA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230052191-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2023-02-16 | — | — | US | disclosed |
| US-20200369658-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2020-11-26 | — | — | US | disclosed |
| US-10774078-B2 | Compounds | MISSION THERAPEUTICS LTD (GB) | 2020-09-15 | — | — | US | disclosed |
| US-20190330202-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2019-10-31 | — | — | US | disclosed |
| US-10392380-B2 | Compounds | MISSION THERAPEUTICS LIMITED (GB) | 2019-08-27 | — | — | US | disclosed |
| US-20180162852-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LIMITED | 2018-06-14 | — | — | US | disclosed |
| US-20180162852-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LIMITED | 2018-06-14 | — | — | US | disclosed |
| US-9926307-B2 | Compounds | MISSION THERAPEUTICS LTD (GB) | 2018-03-27 | — | — | US | disclosed |
| US-9926307-B2 | Compounds | MISSION THERAPEUTICS LTD (GB) | 2018-03-27 | — | — | US | disclosed |
| US-20170247365-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2017-08-31 | — | — | US | disclosed |
| US-20170247365-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2017-08-31 | — | — | US | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | CASR 1397/4885MAPK14 2803/4885KDM4E 4854/4885 |
| US-10774078-B2 | Compounds | UCHL1, UCHL3, UCHL5 | CASR 4740/4885MAPK14 3850/4885KDM4E 175/4885 |
| US-20180162852-A1 | NOVEL COMPOUNDS | UCHL1, UCHL3, UCHL5 | CASR 4660/4885MAPK14 4014/4885KDM4E 178/4885 |
| US-10392380-B2 | Compounds | UCHL1, UCHL3, UCHL5 | CASR 4740/4885MAPK14 3850/4885KDM4E 175/4885 |
| US-20200369658-A1 | NOVEL COMPOUNDS | UCHL1, UCHL3, UCHL5 | CASR 4660/4885MAPK14 4014/4885KDM4E 178/4885 |
| US-20190330202-A1 | NOVEL COMPOUNDS | UCHL1, UCHL3, UCHL5 | CASR 4660/4885MAPK14 4014/4885KDM4E 178/4885 |
| US-20170247365-A1 | NOVEL COMPOUNDS | UCHL1, UCHL3, UCHL5 | CASR 4660/4885MAPK14 4014/4885KDM4E 178/4885 |
| US-20230052191-A1 | NOVEL COMPOUNDS | UCHL1, UCHL3, UCHL5 | CASR 4660/4885MAPK14 4014/4885KDM4E 178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.